Apathy and impulsivity are common and often coexistent consequences of frontotemporal lobar degeneration (FTLD). They increase patient morbidity and carer distress, but remain under-estimated and poorly treated. Recent trans-diagnostic approaches that span the spectrum of clinical presentations of FTLD and parkinsonism, indicate that apathy and impulsivity can be fractionated into multiple neuroanatomical and pharmacological systems. These include ventral/dorsal frontostriatal circuits for reward-sensitivity, responseinhibition, and decision-making; moderated by noradrenaline, dopamine, and serotonin. Improved assessment tools, formal models of cognition and behavior, combined with brain imaging and psychopharmacology, are creating new therapeutic targets and establishing principles for stratification in future clinical trials.
Introduction
Apathy and impulsivity are two problems that coexist in frontotemporal lobar degeneration (FTLD) syndromes, including the behavioral variant of frontotemporal dementia (bvFTD), primary progressive aphasia, progressive supranuclear palsy (PSP), and corticobasal syndrome [1,2,3 ,4] . Epidemiological data indicate that apathy and impulsivity are common in FTLD syndromes [5] , and cause significant patient morbidity and carer distress. Despite progress in understanding apathy and impulsivity in other diseases [6] , there is a limited evidence base for clinical management in FTLD syndromes.
Apathy and impulsivity have been conceived as belonging to opposite ends of a behavioral spectrum of dopamine-dependent abnormal motivation [7] . Although relevant to some aspects of apathy and impulsivity in certain neuropsychiatric disorders, this approach cannot explain their frequent co-occurrence in FTLD, or the fact that FTLD patients with more apathy also manifest more impulsivity (Figure 1 ) [8 ] . As a concrete illustration of their co-existence, we commonly observe apathetic patients (e.g. sitting in a chair for hours) whose first action in the day is an uncontrolled and impulsive movement that put them at risk of falling and reporting injuries. This 'alliance' of apathy and impulsivity is also acknowledged in the clinical diagnostic criteria for bvFTD [4] and PSP [3 ] .
We propose that apathy and impulsivity are behavioral constructs with multiple components, and that these components are positively correlated due to commonalities in neuroanatomical and pharmacological consequences of pathology, leading to dysregulation of decision-making, response-inhibition, and motivation. Alternatively, apathy and impulsivity may originate from separate brain structures and pharmacological mechanisms which are difficult to fractionate empirically due to the widespread nature of the FTLD-related pathological changes. However, the co-existence of apathy and impulsivity in other, non-degenerative, conditions (e.g. drug addiction) suggests that this latter hypothesis is less likely [9, 10] .
In parallel with correlative investigations of the neuroanatomical substrates of apathy and impulsivity, we present a computational approach embedded in the decision theory to describe and characterize the co-existence of apathy and impulsivity in FTLD syndromes in terms of latent neurocognitive mechanisms [11, 12] .
Finally, we highlight the role played by neurotransmitters other than dopamine, in part because apathy and impulsivity in FTLD are clinically unresponsive to standard dopaminergic therapies and in part because of emerging evidence of serotonergic and noradrenergic contributions to both apathy and impulsivity [13] [14] [15] [16] . 
